Iridex Corp Posts Softer Revenue and Wider Quarterly Loss in Interim Filing

Bottom line

- The interim filing under 0001193125-26-355641 for IRIDEX CORP (IRIX, CIK 0001006045) is a Form 10-Q covering period-ended-2026-07-04, and the reader-facing analytics in this section are scoped to that filing alone. - Across the three-month reporting period the three months ended July 4, 2026, the company reported Revenue from Contract with Customer, Excluding Assessed Tax of $12,566,000 USD, against a prior-year comparison of $13,571,000 USD for the three months ended June 28, 2025; the authorized direction is a decrease on a positive base.

- Across the six-month year-to-date window the six months ended July 4, 2026, Revenue from Contract with Customer, Excluding Assessed Tax was $24,365,000 USD, against a prior-year comparison of $25,467,000 USD for the six months ended June 28, 2025; the authorized direction is a decrease on a positive base. - Operating Income (Loss) for the quarter was -$1,029,000 USD, compared with -$940,000 USD in the prior-year quarter; the authorized direction is a decrease, with the transition labelled loss to loss. - Operating Income (Loss) for the six-month year-to-date window was -$1,353,000 USD, against -$1,145,000 USD in the prior-year six-month window; the authorized direction is a decrease, with the transition labelled loss to loss.

- Net Income (Loss) Attributable to Parent for the quarter was -$1,266,000 USD, against -$994,000 USD in the prior-year quarter; the authorized direction is a decrease, with the transition labelled loss to loss. - Net Income (Loss) Attributable to Parent for the six-month year-to-date window was -$1,790,000 USD, against -$2,680,000 USD in the prior-year six-month window; the authorized direction is an increase, with the transition labelled loss to loss. 06 per diluted share USD/SHARES in the prior-year quarter; the authorized direction is a decrease, with the transition labelled loss to loss.

16 per diluted share USD/SHARES in the prior-year six-month window; the authorized direction is an increase, with the transition labelled loss to loss. - The filing includes a forward-looking-statements narrative that the prospective items in this report may be affected by macroeconomic conditions, foreign-exchange and interest-rate movements, customer acceptance of existing and new products, competition, the Topcon Corporation strategic partnership, manufacturing and supply-chain reliance, and Nasdaq continued-listing compliance, among other factors cited under the forward-looking statements section; the cited note frames each of these as a risk to forward-looking statements rather than a quantified explanation of the reported quarter or six-month movement.

- The reader can observe that the quarter moved in a worse direction than the same quarter a year earlier on revenue, operating loss, net loss, and diluted EPS, while the six-month year-to-date window showed divergent authorized directions across the same metrics, including a narrower net loss and a narrower diluted loss against the prior-year six-month base; a peer or industry benchmark is not part of the filing evidence, so any cross-company comparison would be unsupported. - None within the filing; the available quoted narrative is limited to the forward-looking-statements block and the catalogued values, and the catalog does not list a counter-narrative or a management rebuttal to the reported declines.

- The filing evidence does not attribute the quarter-over-quarter revenue decline or the operating-loss movement to any single cause, and the cited note does not break out segment-level detail for these dimensions, so a cause statement and a segment statement are not produced here. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

- The filing evidence does not disclose segment-level detail for this dimension.

Financial performance

- Revenue from Contract with Customer, Excluding Assessed Tax was $13,571,000 USD for the three months ended June 28, 2025 and $12,566,000 USD for the three months ended July 4, 2026, an authorized decrease year-over-year on the three-month reporting window. The same line on the six-month year-to-date window compares $25,467,000 USD for the six months ended June 28, 2025 with $24,365,000 USD for the six months ended July 4, 2026, also an authorized decrease, so the top-line softening is consistent across both reported horizons.

The filing evidence does not attribute this change to any single cause. - Operating Income (Loss) was -$940,000 USD for the three months ended June 28, 2025 versus -$1,029,000 USD for the three months ended July 4, 2026, an authorized decrease on the quarter. On the year-to-date window, Operating Income (Loss) moved from -$1,145,000 USD for the six months ended June 28, 2025 to -$1,353,000 USD for the six months ended July 4, 2026, also an authorized decrease, and both periods remain losses.

The filing evidence does not attribute this change to any single cause. - Net Income (Loss) Attributable to Parent was -$994,000 USD for the three months ended June 28, 2025 against -$1,266,000 USD for the three months ended July 4, 2026, an authorized decrease on the quarter and a loss-to-loss transition. On the year-to-date window, the figure went from -$2,680,000 USD for the six months ended June 28, 2025 to -$1,790,000 USD for the six months ended July 4, 2026, an authorized increase that is still a loss-to-loss transition.

The filing evidence does not attribute this change to any single cause. 07 per diluted share USD/SHARES for the three months ended July 4, 2026, an authorized decrease on the quarter and a loss-to-loss transition. 1 per diluted share USD/SHARES for the six months ended July 4, 2026, an authorized increase that is still a loss-to-loss transition.

The filing evidence does not attribute this change to any single cause. - Accounting context: the filing is the quarterly report on 10-Q for period-ended-2026-07-04 filed under accession 0001193125-26-355641 by IRIDEX CORP (CIK 0001006045, ticker IRIX). S.

GAAP and include only normal recurring adjustments, so the year-over-year movement is not the product of a one-time accounting reset disclosed in this filing. Management explicitly cautions that the three- and six-month results are not necessarily indicative of the full fiscal year or any future interim period, which is the relevant baseline caveat for any reader extrapolating the comparison. - The Company manages its operations as a single segment with the Chief Executive Officer acting as the Chief Operating Decision Maker, allocating resources and evaluating performance at the consolidated level using revenues, gross profit, income from operations, and other key financial data; segment disclosures are therefore not provided separately in this filing.

S. and Germany are direct-to-end-user markets while other geographies are served through independent third-party distributors, which is the mix relevant to any quarter-over-quarter and year-over-year revenue baseline. A similar loss-on-softening-revenue pattern is visible in Starz Entertainment Posts Wider Losses on Softer Revenue in Interim Filing.

- Comparison baselines: the only authorized year-over-year directions available in this section are those listed above for revenue, operating loss, net loss, and diluted EPS across both windows. Management does not provide quantitative forward guidance in this filing, and the forward-looking statement note in Item 6 and the legal-proceedings and risk-factor references in Item 1 and Item 1A do not extend those baselines. The filing evidence contains no peer or industry comparison.

Operating drivers and segments

IRIDEX CORP IRIX operates as a single reportable segment for purposes of assessing performance and making operating decisions, as disclosed in the cited segment-reporting note. Because the company manages and reports as one segment, there is no segment-level revenue or operating-income split available for the three-month reporting period the three months ended July 4, 2026 or the six-month year-to-date period the six months ended July 4, 2026 in this 10-Q. Revenue from Contract with Customer, Excluding Assessed Tax for the three-month reporting period the three months ended July 4, 2026 was $12,566,000 USD, against $13,571,000 USD in the prior-year comparative the three months ended June 28, 2025, with the authorized comparison indicating a decrease. Revenue for the six-month year-to-date period the six months ended July 4, 2026 was $24,365,000 USD, against $25,467,000 USD in the six months ended June 28, 2025, also flagged as a decrease on the authorized comparison. Operating Income (Loss) for the three months ended July 4, 2026 was -$1,029,000 USD, against -$940,000 USD in the prior-year comparative, with the authorized comparison indicating a decrease in loss. Operating Income (Loss) for the six months ended July 4, 2026 was -$1,353,000 USD, against -$1,145,000 USD in the prior-year comparative, again with the authorized comparison indicating a decrease. The cited note provides no per-region, per-product, or per-channel split to triangulate the revenue contraction independently of consolidated totals.

Management frames forward-looking commentary around a broad list of drivers, including future financial performance (revenue, cost of revenue, gross profit or gross margin, and operating-expense lines), macroeconomic conditions, customer acceptance and purchase of existing and new products, competition, foreign currency and interest-rate effects, innovation pace, manufacturing costs, the strategic partnership with Topcon Corporation, demand forecasting, defect discovery, international sales strategy, operating results and cash flows, intellectual-property and information-technology protection, goodwill carrying value, equity-award expensing, litigation defense, director and officer indemnification, indebtedness management, geographic expansion, regulatory compliance, talent retention, Nasdaq continued-listing compliance, additional capital raising, preferred-stock issuance, common-stock trading prices, and future dividend capacity, as referenced in the cited note. Management also cautions that forward-looking statements rest on information available as of the 10-Q and may be limited or incomplete, and that actual results may differ materially from expectations. In this filing, management does not isolate which of these factors explains the year-over-year change in revenue or operating loss on either reported window.

The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison. The single-segment structure limits any independent cross-check against product-line or geographic peers within this filing, and the cited note does not provide a quantified bridge between revenue and operating loss for either window. For a contrast in how wider losses can present alongside softer top-line results, readers may also review Starz Entertainment Posts Wider Losses on Softer Revenue in Interim Filing.

Cash flow and capital

On the operating side, Net Cash Provided by (Used in) Operating Activities moved in opposite directions in the two halves of the comparison, but both windows registered cash usage. The current six-month year-to-date figure reported in this 10-Q for period-ended-2026-07-04 under accession 0001193125-26-355641 (entity IRIDEX CORP, ticker IRIX, CIK 0001006045) was negative, and the prior-year comparative for the six months ended June 28, 2025 was likewise negative, with the current half-year showing a higher cash-burn profile (that is, less cash used, or more cash used, than the prior year depending on the sign convention). Against that backdrop, management does not break out individual working-capital drivers in a separate cash-flow narrative, so any single cause for the change in operating cash usage is not stated — The filing evidence does not attribute this change to any single cause..

Capital expenditure disclosures add a second layer to the cash picture. Payments to Acquire Property, Plant, and Equipment, recorded in the investing-activities section, were positive in both the current six-month year-to-date window the six months ended July 4, 2026 and the prior-year comparative the six months ended June 28, 2025, indicating that the company continued to spend on property, plant, and equipment in both periods, with the current period showing a higher cash outlay for these assets. The full investing line — Net Cash Provided by (Used in) Investing Activities — was negative in both windows and moved to a larger cash outflow in the current half-year relative to the prior-year period, consistent with heavier capital outlays absorbing cash.

Financing activity flipped sign year over year. Net Cash Provided by (Used in) Financing Activities was positive in the prior-year six-month period and negative in the current six-month period the six months ended July 4, 2026, signaling a swing from a net cash inflow to a net cash outflow, while the prior-year comparative window the six months ended June 28, 2025 had shown a net inflow. The company does not, in the cash-flow statement itself, itemize the instruments behind this swing, so the underlying cause — repayment versus issuance, lease versus equity — The filing evidence does not attribute this change to any single cause..

Turning to the balance sheet at the balance sheet date of July 4, 2026, three current-asset and current-liability line items frame the liquidity position: Cash and Cash Equivalents, at Carrying Value stood at $4,680,000; Accounts Receivable, after Allowance for Credit Loss, Current was $5,674,000; and Accounts Payable, Current was $6,650,000. The reported stockholders' equity disclosure in Note 8 describes the preferred-stock authorization but does not translate that into a numeric cushion here, and segment-level detail of these balances is not disclosed — The filing evidence does not disclose segment-level detail for this dimension.. Management's discussion of capital allocation is also light in this filing: the prior periods' other information items (covering risk factors, controls, and other legal and procedural matters in Item 1, Item 1A, Item 2, Item 3, Item 4, Item 5, and Item 6) do not contain a dedicated capital-return or buyback program section.

Net-net, the cash-flow profile is one of a higher operating cash burn, higher capital spending, and a financing line that moved from inflow to outflow — a combination that pressures the cash balance carried on the balance sheet. Investors looking to compare this trajectory against peers can reference the Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows for contrast, but The filing evidence contains no peer or industry comparison. within this specific filing.

Peer and historical context

The interim filing for IRIDEX CORP (IRIX) under 10-Q for period-ended-2026-07-04 (accession 0001193125-26-355641) frames its results almost entirely against the company's own prior-year comparisons, leaving industry-wide peer benchmarking outside the quoted evidence. The filing evidence contains no peer or industry comparison. Within that self-referential frame, the half-year view covers the six months ended July 4, 2026 against the six months ended June 28, 2025, while the quarterly view compares the three months ended in the three months ended July 4, 2026 with the three months ended June 28, 2025.

On the top line, $24,365,000 for the six-month window sits below $25,467,000, and the single-quarter reading in $12,566,000 is similarly lower than $13,571,000; the contract-revenue narrative describes warranty, system-repair, royalty, and exclusive distribution revenue streams but offers no read-through to the size or direction of the change. The filing evidence does not attribute this change to any single cause. Operating profitability has compressed alongside the top line: both -$1,353,000 and -$1,029,000 are larger losses than -$1,145,000 and -$940,000 respectively, reinforcing a pattern of widening near-term operating drag.

Net income continues to be negative across every window shown. -$1,790,000 for the half year remains a loss but is a smaller loss than -$2,680,000, indicating a modest half-year reprieve at the bottom line even as the operating line deepens. -$1,266,000 for the three-month period, however, is a wider loss than -$994,000. Cash from operations stays negative in both periods: -$1,161,000 improved relative to -$1,546,000, suggesting the company is burning through cash more slowly than the prior year even while remaining in outflow territory.

For readers who triangulate interim filings, the directional pattern here — softer revenue, deeper quarterly operating loss, half-year net-loss contraction, and improved operating cash burn — is reminiscent of the wider-losses, softer-revenue profile described in Starz Entertainment Posts Wider Losses on Softer Revenue in Interim Filing, though no direct peer comparison data is provided in this filing. Segment-level breakouts are also not part of the quoted evidence. The filing evidence does not disclose segment-level detail for this dimension. Outside of the cited revenue-recognition note (Note 8), no additional disaggregation is offered that would help frame the historical drift against category peers.

Scenario analysis

- In the base case, IRIDEX CORP continues on the path visible in the latest interim filing, with revenue trending lower year-over-year on both reported windows while the bottom line remains in a loss position. - Reported facts: Revenue from Contract with Customer, Excluding Assessed Tax was $12,566,000 USD for the three months ended July 4, 2026, against the prior-year comparative of $13,571,000 USD for the three months ended June 28, 2025, and was $24,365,000 USD for the six months ended July 4, 2026 against $25,467,000 USD for the six months ended June 28, 2025. - Reported facts: Net Income (Loss) Attributable to Parent was -$1,266,000 USD for the three months ended July 4, 2026, against -$994,000 USD for the three months ended June 28, 2025, and was -$1,790,000 USD for the six months ended July 4, 2026 against -$2,680,000 USD for the six months ended June 28, 2025. - Both the quarter and the six-month year-to-date period therefore show declines on the top line relative to the prior-year comparatives, while the bottom line remains a loss rather than a profit on both windows. - Management explanations: The cited note describes the exclusive-distribution arrangement with Topcon, the deferral and amortization of contract costs, and the treatment of operating leases; none of these disclosures, on their own, provide a basis for an upward or downward re-rating in the base case. - Analyst inference: In the base case the reader should treat the reported decline in revenue and the loss persistence as the operating baseline until new disclosures appear. - Counter-evidence: The arrangements described in the cited note (the Topcon exclusivity rights, the deferred costs amortized on a straight-line basis, the operating-lease ROU assets) are forward-looking levers, but the filing evidence does not show their incremental revenue or cost impact. - Unknowns: Any driver behind the lower revenue versus the prior year is not separately disclosed for these windows; treat that gap as The filing evidence does not attribute this change to any single cause..

- In the upside case, the Topcon exclusive-distribution rights ramp through regulatory approval over time and contribute to a stabilization of Revenue from Contract with Customer, Excluding Assessed Tax relative to $25,467,000 and $13,571,000. - Reported facts: Revenue from Contract with Customer, Excluding Assessed Tax on the latest the three months ended July 4, 2026 sits at $12,566,000 USD and on the six months ended July 4, 2026 at $24,365,000 USD, lower than the prior-year comparatives listed above; recovery in the upside case is therefore relative, not absolute. - Management explanations: The cited note states that the estimated fair value of the exclusive-distribution rights across all regions combined totaled approximately the figure shown above in that disclosure, and that management returned to Topcon the fee allocated to one region because the regulatory path was not feasible. - Analyst inference: The upside path depends on the remaining regions progressing through regulatory approval, which the cited note frames as the trigger for straight-line revenue recognition. - Counter-evidence: Even with the exclusivity in place, Net Income (Loss) Attributable to Parent at -$1,266,000 USD for the three months ended July 4, 2026 and at -$1,790,000 USD for the six months ended July 4, 2026 remains a loss rather than a profit, so the upside scenario is a narrowing of the loss rather than a swing to profitability based on the disclosed numbers. - Unknowns: Region-by-region timing of regulatory approval is not stated; treat region-level timing as The filing evidence does not attribute this change to any single cause. at the company-aggregate level.

- In the downside case, Revenue from Contract with Customer, Excluding Assessed Tax extends the decline already visible at $12,566,000 USD versus $13,571,000 USD and at $24,365,000 USD versus $25,467,000 USD. - Reported facts: Net Income (Loss) Attributable to Parent is already a loss at -$1,266,000 USD for the three months ended July 4, 2026 and at -$1,790,000 USD for the six months ended July 4, 2026, against prior-year loss comparatives of -$994,000 USD and -$2,680,000 USD; the downside path widens these losses rather than introducing a new line item not already visible. - Management explanations: The cited note confirms that some contract costs are deferred and amortized on a straight-line basis, which means margin in the downside case is shaped by both the rate of revenue decline and the pace of amortization. - Analyst inference: In the downside view, the disclosed concentration of cash deposits and the open-credit terms with international distributors, as described in the cited note, raise the operational sensitivity of a continuing revenue decline. - Counter-evidence: The same cited note states that as of the recent balance-sheet date the Company had fully recognized certain deferred costs, which limits any one-time write-down risk tied to those balances. - Unknowns: Management does not disclose a region-by-region revenue path in the filing, so any link between Topcon exclusivity timing and a wider loss is The filing evidence does not attribute this change to any single cause..

Risks and what to watch

- Reported facts: The six-month year-to-date and three-month reporting windows in this interim filing, filed under 10-Q period-ended-2026-07-04 (accession 0001193125-26-355641) by IRIDEX CORP (IRIX, CIK 0001006045), both show a top-line contraction alongside a wider loss. Revenue from Contract with Customer, Excluding Assessed Tax for the six-month year-to-date period the six months ended July 4, 2026 was $24,365,000 USD, lower than the prior-year comparative the six months ended June 28, 2025 figure of $25,467,000 USD. The same pattern appears on the three-month view: the three months ended July 4, 2026 revenue was $12,566,000 USD versus $13,571,000 USD for the three months ended June 28, 2025. Net Income (Loss) Attributable to Parent was a loss of -$1,790,000 USD for the six months ended July 4, 2026 versus a loss of -$2,680,000 USD for the six months ended June 28, 2025, and a loss of -$1,266,000 USD for the three months ended July 4, 2026 versus a loss of -$994,000 USD for the three months ended June 28, 2025. The accounting policy note confirms deferred contract-fulfillment costs are amortized systematically against the related revenue, which ties the revenue line to the balance-sheet items described in the same passage.

- Management explanations: Management cites an optional practical expedient under which sales commissions with an amortization period of one year or less are expensed as incurred rather than capitalized, and treats contract-fulfillment costs as an asset when directly attributable to specific performance obligations and expected to be recovered. Operating leases are recognized using the incremental borrowing rate at the commencement date, with lease and non-lease components combined as a single lease component. The narrative on credit risk notes that cash is held in demand and money market accounts, that deposits may exceed insured limits, and that international distributor sales are generally made on open credit terms and letters of credit.

- Analyst inference: The combination of lower revenue in both reported periods together with a loss attributable to parent that also worsened on the quarter, even though it narrowed on the six-month view, is consistent with operating deleverage but does not in itself point to a single driver. The filing evidence does not attribute this change to any single cause. The treatment of commission costs and contract-fulfillment assets means that reported revenue and expense recognition are interlinked through the cited accounting policy, so a change in deferred costs could affect both lines without a change in underlying cash receipts.

- Counter-evidence and unknowns: None of the authorized year-over-year comparisons reverse the revenue decline or the quarterly loss deterioration. The filing evidence does not attribute this change to any single cause. The filing evidence does not disclose segment-level detail for this dimension. The filing evidence contains no peer or industry comparison. The deferred costs figure cited in the narrative is shown as (omitted) million in the source, so the magnitude of the related balance-sheet item cannot be quoted.

- Metrics to watch next period: - Revenue trajectory on both the quarter and the six-month windows, given the year-over-year decline. - Net Income (Loss) Attributable to Parent on the quarterly window, which moved from one loss to a wider loss. - Contract-fulfillment cost balances and their amortization, since the cited policy links them to revenue recognition. - Disclosure updates under Item 1A on risk factors and any concentration-of-credit developments noted in the relevant cited note.